› Forums › General Melanoma Community › Adoptive cell therapy treatment only when all else fails?
- This topic has 15 replies, 4 voices, and was last updated 10 years, 6 months ago by
JerryfromFauq.
- Post
-
- March 8, 2015 at 4:12 pm
To put it bluntly my question is should adoptive cell therapy only be considered when all other options have been exhausted? From my recent experience this seems to the dominant medical thinking.
A little background.
I've been lurking on this message board since my diagnosis of stage 4 metastatic melanoma in October 2014 that followed 5-6 mothns of chest and back pain that included 4 boken ribs. The cancer is in every bone above my knees and I have 5-6 large tumors throughout my body, with especially large one's in my ribs and spine.
Did the 4 treatment regiment of Yervoy and two 10 dose rounds of radiation from October to December. Also took ten daily shots of leukine with last Yervoy treatment. Immediatley my level of pain went down and things were pretty good until about a month ago.
I've started having back and chest the last 4-5 weeks and there is blood in my spit. Pet scan about a month ago showed all tumors stable except one lesion that is where the pain is.
At some point I read about adotpive cell therapy on this website and have tried to read as much about as I can in medical journal articles using google scholar. As I understand it there are good response rates and even complete recovery rates that vary from 10 to 40 percent.
Last week I went to a melanoma specialist and his opinion matched my doctor at the regional cancer center I go to. They say there are just as good results without having to spend weeks in the hospital.
The specialist wants me to go on the combo of dabrafenib and trametinib. See how long that woks and then go on anti-PD 1 when the tumors start growing again.
I guess I just want to be more aggresive than the doctors. So back to my question. Should I only consider adotpive cell once all else has failed–which I think is going to happen anyway.
Sorry for the length and I greatly appreciate any comments or opinions.
- Replies
-
-
- March 8, 2015 at 4:59 pm
I think that the most reasonable thing to do is to seek a second or even third opinion from melanoma experts, especially from someone with experience of adoptive cell therapy.
Just one question from me: Is there any way that you could get anti PD1 rather than BRAF/MEK at this stage? It would make sense to try immunotherapy first since there is a chance to have a durable response even off the drug, which has not yet been proven with BRAF/MEK. From what I have read, prior immunotherapy might also increase the effect of adoptive cell therapy. Please just take this as a question to ask the doctor since I am not a doctor.
-
- March 8, 2015 at 4:59 pm
I think that the most reasonable thing to do is to seek a second or even third opinion from melanoma experts, especially from someone with experience of adoptive cell therapy.
Just one question from me: Is there any way that you could get anti PD1 rather than BRAF/MEK at this stage? It would make sense to try immunotherapy first since there is a chance to have a durable response even off the drug, which has not yet been proven with BRAF/MEK. From what I have read, prior immunotherapy might also increase the effect of adoptive cell therapy. Please just take this as a question to ask the doctor since I am not a doctor.
-
- March 8, 2015 at 4:59 pm
I think that the most reasonable thing to do is to seek a second or even third opinion from melanoma experts, especially from someone with experience of adoptive cell therapy.
Just one question from me: Is there any way that you could get anti PD1 rather than BRAF/MEK at this stage? It would make sense to try immunotherapy first since there is a chance to have a durable response even off the drug, which has not yet been proven with BRAF/MEK. From what I have read, prior immunotherapy might also increase the effect of adoptive cell therapy. Please just take this as a question to ask the doctor since I am not a doctor.
-
- March 8, 2015 at 8:39 pm
No. Some people on here did it as their first treatment. However the success rate is rather skewed from what I was told. They basically claim it is a 50/50 response rate. They cherry pick their patients they accept among other things. However that being said if a person is strong and healthy I would think it is a viable option. Those of us that have been battered by treatments and disease for so long and are no longer very healthy probably should stay away from it because a number of people don't make it back from the drop to zero white blood cell part and if they do they don't recover from the rest of the treatment. Thus being healthy and strong going into it is very important and you can do it fine. Thus doing it earlier instead of later seems better to me.
to skip the braf pills and go straight to pd1 requires a trial. The fda requires us braf positive folks to fail it before we can get the fda approved pd1. Maybe that will change. Also don't count out the miracle of pd1. For me 19 out of 30 tumors were shrinking after only 3 doses. 7 were growing. Those all started as bone tumors too. I had failed with nothing shrinking both brafs and ipi. Second scan showed some tumors had mild growth. Soon to have third scan.
I also wanted to make sure your doc has offered xgeva or zometa for your bones especially the spine.
but yeah if you are strong and healthy enough I would do it now rather than later.
Artie
-
- March 8, 2015 at 8:39 pm
No. Some people on here did it as their first treatment. However the success rate is rather skewed from what I was told. They basically claim it is a 50/50 response rate. They cherry pick their patients they accept among other things. However that being said if a person is strong and healthy I would think it is a viable option. Those of us that have been battered by treatments and disease for so long and are no longer very healthy probably should stay away from it because a number of people don't make it back from the drop to zero white blood cell part and if they do they don't recover from the rest of the treatment. Thus being healthy and strong going into it is very important and you can do it fine. Thus doing it earlier instead of later seems better to me.
to skip the braf pills and go straight to pd1 requires a trial. The fda requires us braf positive folks to fail it before we can get the fda approved pd1. Maybe that will change. Also don't count out the miracle of pd1. For me 19 out of 30 tumors were shrinking after only 3 doses. 7 were growing. Those all started as bone tumors too. I had failed with nothing shrinking both brafs and ipi. Second scan showed some tumors had mild growth. Soon to have third scan.
I also wanted to make sure your doc has offered xgeva or zometa for your bones especially the spine.
but yeah if you are strong and healthy enough I would do it now rather than later.
Artie
-
- March 8, 2015 at 8:39 pm
No. Some people on here did it as their first treatment. However the success rate is rather skewed from what I was told. They basically claim it is a 50/50 response rate. They cherry pick their patients they accept among other things. However that being said if a person is strong and healthy I would think it is a viable option. Those of us that have been battered by treatments and disease for so long and are no longer very healthy probably should stay away from it because a number of people don't make it back from the drop to zero white blood cell part and if they do they don't recover from the rest of the treatment. Thus being healthy and strong going into it is very important and you can do it fine. Thus doing it earlier instead of later seems better to me.
to skip the braf pills and go straight to pd1 requires a trial. The fda requires us braf positive folks to fail it before we can get the fda approved pd1. Maybe that will change. Also don't count out the miracle of pd1. For me 19 out of 30 tumors were shrinking after only 3 doses. 7 were growing. Those all started as bone tumors too. I had failed with nothing shrinking both brafs and ipi. Second scan showed some tumors had mild growth. Soon to have third scan.
I also wanted to make sure your doc has offered xgeva or zometa for your bones especially the spine.
but yeah if you are strong and healthy enough I would do it now rather than later.
Artie
-
- March 8, 2015 at 11:01 pm
Under Current FDA approvaal, if one is BRAF V600E/K+ then one has to have anti-BRAF- targeted chemo and fail it to get to Yervoy (anti-CTLA-4 immunmotherapy) to fail it to get to one of the milder, but more efective Anti-PD-1 immunotherapy treatments.
When I reached Stage IV, many oncolgists (that were not trained to administer IL-2) were telling people to hold off on IL-2 until the last treatment possible. I talked to many surviving spouses and was told that their deceased spouse had tried to hold it to the last and then failed to recover from the previous treatments in time to try the IL-2. Since I was at my stongest point, I jumped on the iL-2 as my first treatment in 2007, hoping to one of the 5-8% that are actually CURED by the IL-2. I was not a complete responder {by technnical definitions, I was a non-responder since even a partial responder has to have at least a 30% reduction in tumor load}. All that I got was for my wildly growiing, agresssive tumor load to stabilize for two years. During that time I also learned that many other treatments were more effective following the immune systems enhancment from the IL-2 immunotherapy . If I had not tried this so called (by a few) deadly treatment I would not be alive today.
I would love to see a breakdown of the ACT/TIL results based on the timimg of the treatments. Early, late, etc. Under todays FDA approvals the anti-PD-1 trtment are a third line treatmment (following anti-BRAF and anti-CTLA-4) What would the results be if Anati-PD-1 was firsst line, IL-2 was second line and TIL/ACT was the third line? Wonder if we will learn during my lifetime!
IS there a choice to really try ACT/TIL as other than a far down the line treatment? Why don't more people start the TIL/ACT by having the harvest of the TIL's done and then go on to one of the other treatments, (AS though we have a progressive treatment path choice!) One can then go back after the TIL's are grown and been preserved, if the other t retment have failed and continue on the TIL treatment. Just my musings on the subject.
-
- March 8, 2015 at 11:01 pm
Under Current FDA approvaal, if one is BRAF V600E/K+ then one has to have anti-BRAF- targeted chemo and fail it to get to Yervoy (anti-CTLA-4 immunmotherapy) to fail it to get to one of the milder, but more efective Anti-PD-1 immunotherapy treatments.
When I reached Stage IV, many oncolgists (that were not trained to administer IL-2) were telling people to hold off on IL-2 until the last treatment possible. I talked to many surviving spouses and was told that their deceased spouse had tried to hold it to the last and then failed to recover from the previous treatments in time to try the IL-2. Since I was at my stongest point, I jumped on the iL-2 as my first treatment in 2007, hoping to one of the 5-8% that are actually CURED by the IL-2. I was not a complete responder {by technnical definitions, I was a non-responder since even a partial responder has to have at least a 30% reduction in tumor load}. All that I got was for my wildly growiing, agresssive tumor load to stabilize for two years. During that time I also learned that many other treatments were more effective following the immune systems enhancment from the IL-2 immunotherapy . If I had not tried this so called (by a few) deadly treatment I would not be alive today.
I would love to see a breakdown of the ACT/TIL results based on the timimg of the treatments. Early, late, etc. Under todays FDA approvals the anti-PD-1 trtment are a third line treatmment (following anti-BRAF and anti-CTLA-4) What would the results be if Anati-PD-1 was firsst line, IL-2 was second line and TIL/ACT was the third line? Wonder if we will learn during my lifetime!
IS there a choice to really try ACT/TIL as other than a far down the line treatment? Why don't more people start the TIL/ACT by having the harvest of the TIL's done and then go on to one of the other treatments, (AS though we have a progressive treatment path choice!) One can then go back after the TIL's are grown and been preserved, if the other t retment have failed and continue on the TIL treatment. Just my musings on the subject.
-
- March 8, 2015 at 11:01 pm
Under Current FDA approvaal, if one is BRAF V600E/K+ then one has to have anti-BRAF- targeted chemo and fail it to get to Yervoy (anti-CTLA-4 immunmotherapy) to fail it to get to one of the milder, but more efective Anti-PD-1 immunotherapy treatments.
When I reached Stage IV, many oncolgists (that were not trained to administer IL-2) were telling people to hold off on IL-2 until the last treatment possible. I talked to many surviving spouses and was told that their deceased spouse had tried to hold it to the last and then failed to recover from the previous treatments in time to try the IL-2. Since I was at my stongest point, I jumped on the iL-2 as my first treatment in 2007, hoping to one of the 5-8% that are actually CURED by the IL-2. I was not a complete responder {by technnical definitions, I was a non-responder since even a partial responder has to have at least a 30% reduction in tumor load}. All that I got was for my wildly growiing, agresssive tumor load to stabilize for two years. During that time I also learned that many other treatments were more effective following the immune systems enhancment from the IL-2 immunotherapy . If I had not tried this so called (by a few) deadly treatment I would not be alive today.
I would love to see a breakdown of the ACT/TIL results based on the timimg of the treatments. Early, late, etc. Under todays FDA approvals the anti-PD-1 trtment are a third line treatmment (following anti-BRAF and anti-CTLA-4) What would the results be if Anati-PD-1 was firsst line, IL-2 was second line and TIL/ACT was the third line? Wonder if we will learn during my lifetime!
IS there a choice to really try ACT/TIL as other than a far down the line treatment? Why don't more people start the TIL/ACT by having the harvest of the TIL's done and then go on to one of the other treatments, (AS though we have a progressive treatment path choice!) One can then go back after the TIL's are grown and been preserved, if the other t retment have failed and continue on the TIL treatment. Just my musings on the subject.
-
- March 8, 2015 at 11:11 pm
Dear Banders, my advice on Adoptive Therapy is talk to the best in the field. My understanding is Patwick Hwu M.D. at MD Anderson in Houston, Texas is the person to talk to. He is one of the leading Dr. in this field and I would think the best place to go for information and stat. Wishing you the best!!!! Ed
-
- March 8, 2015 at 11:11 pm
Dear Banders, my advice on Adoptive Therapy is talk to the best in the field. My understanding is Patwick Hwu M.D. at MD Anderson in Houston, Texas is the person to talk to. He is one of the leading Dr. in this field and I would think the best place to go for information and stat. Wishing you the best!!!! Ed
-
- March 11, 2015 at 2:39 pm
The Father of TIL/ACT : http://home.ccr.cancer.gov/connections/2014/Vol8_No1/intheclinic.asp
Adopting Bodily Defenses to Cure Cancer
Steven Rosenberg, M.D., Ph.D., Chief of CCR’s Surgery Branch since 1974, is a genuine pioneer in the development of immunotherapies for cancer. In 1985, he was the first to demonstrate that an immunotherapy—specifically, the administration of interleukin-2 (IL-2)—could cure certain patients with metastatic disease. A few years later, he opened the doors to cell-based immunotherapies by showing that tumor-infiltrating T lymphocytes (TILs) could be isolated from melanomas, stimulated to proliferate, and reintroduced into patients to promote cancer regression. Since that time, Rosenberg and his colleagues have discovered and developed innovative ways to improve upon cell transfer therapies. He was the first to insert foreign genes into humans in 1990 and the first to demonstrate that genetic modification of T cells could mediate cancer regression in patients with melanoma, sarcomas, and lymphomas. Rosenberg has written more than 1,100 scientific articles, as well as eight books, and was the most cited clinician in the world in the field of oncology between 1981 and 1998.
-
- March 11, 2015 at 2:39 pm
The Father of TIL/ACT : http://home.ccr.cancer.gov/connections/2014/Vol8_No1/intheclinic.asp
Adopting Bodily Defenses to Cure Cancer
Steven Rosenberg, M.D., Ph.D., Chief of CCR’s Surgery Branch since 1974, is a genuine pioneer in the development of immunotherapies for cancer. In 1985, he was the first to demonstrate that an immunotherapy—specifically, the administration of interleukin-2 (IL-2)—could cure certain patients with metastatic disease. A few years later, he opened the doors to cell-based immunotherapies by showing that tumor-infiltrating T lymphocytes (TILs) could be isolated from melanomas, stimulated to proliferate, and reintroduced into patients to promote cancer regression. Since that time, Rosenberg and his colleagues have discovered and developed innovative ways to improve upon cell transfer therapies. He was the first to insert foreign genes into humans in 1990 and the first to demonstrate that genetic modification of T cells could mediate cancer regression in patients with melanoma, sarcomas, and lymphomas. Rosenberg has written more than 1,100 scientific articles, as well as eight books, and was the most cited clinician in the world in the field of oncology between 1981 and 1998.
-
- March 11, 2015 at 2:39 pm
The Father of TIL/ACT : http://home.ccr.cancer.gov/connections/2014/Vol8_No1/intheclinic.asp
Adopting Bodily Defenses to Cure Cancer
Steven Rosenberg, M.D., Ph.D., Chief of CCR’s Surgery Branch since 1974, is a genuine pioneer in the development of immunotherapies for cancer. In 1985, he was the first to demonstrate that an immunotherapy—specifically, the administration of interleukin-2 (IL-2)—could cure certain patients with metastatic disease. A few years later, he opened the doors to cell-based immunotherapies by showing that tumor-infiltrating T lymphocytes (TILs) could be isolated from melanomas, stimulated to proliferate, and reintroduced into patients to promote cancer regression. Since that time, Rosenberg and his colleagues have discovered and developed innovative ways to improve upon cell transfer therapies. He was the first to insert foreign genes into humans in 1990 and the first to demonstrate that genetic modification of T cells could mediate cancer regression in patients with melanoma, sarcomas, and lymphomas. Rosenberg has written more than 1,100 scientific articles, as well as eight books, and was the most cited clinician in the world in the field of oncology between 1981 and 1998.
-
- March 8, 2015 at 11:11 pm
Dear Banders, my advice on Adoptive Therapy is talk to the best in the field. My understanding is Patwick Hwu M.D. at MD Anderson in Houston, Texas is the person to talk to. He is one of the leading Dr. in this field and I would think the best place to go for information and stat. Wishing you the best!!!! Ed
-
- You must be logged in to reply to this topic.